Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 79,327 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Recurrent Merkel Cell Carcinoma, Stage III Merkel Cell Carcinoma AJCC v7, Stage IIIA Merkel Cell Carcinoma AJCC v7, Stage IIIB Merkel Cell Carcinoma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7
Interventions: Laboratory Biomarker Analysis, Pembrolizumab; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 13
States / cities: Palo Alto, California • San Francisco, California • New Haven, Connecticut + 9 more

Conditions: Gastroesophageal Reflux Disease, GERD, Gastroparesis
Interventions: Domperidone; Drug
Lead sponsor: Scott Gabbard, MD; Other
Eligibility: 18 Years and older
U.S. locations: 2
States / cities: Weston, Florida • Cleveland, Ohio

Conditions: Respiratory Failure, Intracranial Hypertension
Interventions: Esophageal Balloon catheter; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Obesity and Cardiovascular Risk
Interventions: Oral BGE-102, Oral Placebo Matching BGE-102; Drug
Lead sponsor: BioAge Labs, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 16
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 13 more

Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Interventions: Hypericin; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Fairport, New York

Conditions: Sleep Apnea, Obstructive
Interventions: Reach for Equity in Pediatric Obstructive Sleep Evaluation (REPOSE), Usual Care; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 2 Years to 12 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Gram Positive Infection, Concurrent Antibiotic Treatment
Interventions: daptomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 2 Years to 6 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Pancreatic Cancer
Interventions: Onvansertib, NALIRIFOX; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Sleep Problems, Sleep Hygiene
Interventions: Good Nights Sleep Program; Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 7 Years to 10 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Lymphoma
Interventions: bexarotene, methoxsalen, UV light therapy; Drug · Procedure
Lead sponsor: Millennix; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 19
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 14 more

Conditions: Dehydration
Interventions: Formalized clinical assessment of hydration status, Take a measurement of body weight on calibrated scales, "RF wristband" hydration status measurement, Measure capillary refill time with manual stopwatch, "CRT device" hydration status measurement; Other · Device
Lead sponsor: Massachusetts Institute of Technology; Other
Eligibility: 2 Years to 18 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: ALK-positive Advanced Tumors
Interventions: ceritinib, warfarin, midazolam; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Detroit, Michigan • San Antonio, Texas

Conditions: Colorectal Cancer
Interventions: Azacitidine, Capecitabine, Oxaliplatin, Azacitidine MTD; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mild Neurocognitive Disorder, Healthy Aging
Interventions: Transcranial Focused Ultrasound; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 50 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Advanced Solid Cancers, Hematologic Cancers
Interventions: SRF231; Drug
Lead sponsor: Surface Oncology; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New York, New York • San Antonio, Texas

Conditions: Nutrition Poor, Micronutrient Deficiency, Aging
Interventions: Hazelnuts; Other
Lead sponsor: Oregon State University; Other
Eligibility: 55 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Corvallis, Oregon

Conditions: Colorectal Cancer Metastatic
Interventions: CT scan; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: HIV Infections
Interventions: GSK1265744 30mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota

Conditions: Ostomy
Interventions: Standard, Pre-operative Education, Two-week Post Operative Education; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Carmel, Indiana

Conditions: Laboring Women Requesting Neuraxial Labor Analgesia
Interventions: Epidural Technique versus Dural Puncture Epidural Technique versus Combined Spinal Epidural Technique; Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gastroesophageal Cancer
Interventions: nab-paclitaxel, ramucirumab; Drug · Biological
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 11
States / cities: Denver, Colorado • Fort Myers, Florida • Orlando, Florida + 8 more

Conditions: Human Papillomavirus
Interventions: Gardasil; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 27 Years to 45 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Toxicity
Interventions: transdermal DMPS; Drug
Lead sponsor: Banner Health; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Bortezomib, Total-Body Irradiation, Melphalan, Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis; Drug · Radiation · Procedure + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

Treatment Use of Domperidone for Gastroparesis

Safety of Optimal PEEP in NSICU Patients

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

The REPOSE (Reach for Equity in Pediatric Sleep Evaluation) Navigation Intervention

PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Good Nights Sleep Program to Improve Child and Family Sleep

Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma

Hydration Status Evaluation of Dehydrated Children With Experimental Devices

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Azacitidine and CAPOX in Metastatic Colorectal Cancer

tFUS for Memory in mNCD and Healthy Adults

Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

Role of Hazelnut Consumption in Improving Micronutrient Status in Older Adults

Assessing How Normal Variations in CT Scanning Affects Its Interpretation

A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers

Different Levels of Patient Education for Care of Ostomy Site

Comparison of Epidural Labor Pain Relief Techniques on Maternal and Fetal Outcomes

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Study of Gardasil in Mid-Adult Males (MAM)

Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma